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Abstract: Panax ginseng is one of the most commonly used Chinese medicines in China, 
Asia and Western countries. The beneficial effects of ginseng have been attributed to the 
biological activities of its constituents, the ginsenosides. In this review, we summarize 
recent publications on the anti-inflammatory effects of ginseng extracts and ginsenosides 
on cellular responses triggered by different inducers including endotoxin, tumor necrosis 
factor-alpha (TNF-α), interferon-gamma and other stimuli. Proinflammatory cytokines, 
chemokines, adhesion molecules and mediators of inflammation including inducible nitric 
oxide synthase, cyclooxygenase-2 and nitric oxide orchestrate the inflammatory response. 
Ginseng extracts and ginsenosides including Rb1, Rd, Rg1, Rg3, Rh1, Rh2, Rh3 and Rp1 
have been reported to have anti-inflammatory properties in different studies related to 
inflammation. Ginsenosides inhibit different inducers-activated signaling protein kinases 
and transcription factor nuclear factor-kappaB leading to decreases in the production of 
cytokines and mediators of inflammation. The therapeutic potential of ginseng on 
TNF-α-mediated inflammatory diseases is also discussed. Taken together, this summary 
provides evidences for the anti-inflammatory effects of ginseng extracts and ginsenosides 
as well as the underlying mechanisms of their effects on inflammatory diseases. 
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1. Introduction 
Panax ginseng C.A. Meyer (ginseng) was first classified by German botanist Nees Von Esenbeck 
in 1833. It was later renamed by Russian botanist Carl Anton Meyer in 1843 [1]. The name of the 
genus Panax was derived from a Greek word which literally means all-healing or panacea. [2]. 
Ginseng has been used as an herbal remedy in ancient China, Korea, Japan and the Far East for more 
than 5,000 years and the medical efficacy of ginseng was documented in ancient Asian literatures [1,3]. 
Following studies of the uses of ginseng in humans, the beneficial effects of ginseng were recognized 
in Western countries by the 18th century [4]. 
Ginseng belongs to the family Araliaceae. Currently, twelve to thirteen species of ginseng have 
been identified in the genus Panax and their geographical distributions are summarized in a recent 
review [1,3]. Three major species of ginseng including Panax ginseng C. A. Meyer, Panax 
quinquefolium L and Panax notoginseng have been extensively investigated for their physiological 
and pharmacological effects on the human body [5-7]. 
2. Active Components of Panax ginseng 
Ginseng species contain multiple active constituents including ginsenosides, polysaccharides, 
peptides, phytosterols, polyacetylenes, polyacetylenic alcohols and fatty acids that have been shown 
to have different effects on carbohydrate and lipid metabolism, cognition and angiogenesis as well as 
on the function of neuroendocrine, immune, cardiovascular and central nervous systems [2,4]. 
The ginsenosides are the major biologically active compounds of ginseng. Recent studies have 
shown that ginsenosides play important roles in the pharmacological effects of ginseng [3]. 
Structurally, ginsenosides belong to the triterpene dammarane-type saponins and comprise 
triterpenoidal glycosides of the dammar type with glucose, arabinose, xylose or rhamnose [8]. Over 
30 different ginsenosides have been isolated from ginseng and identified [3]. Twenty-two subtypes of 
ginsenosides including Ra1 Ra2, Ra3 Rb1, Rb2, Rb3, Rc, Rd, Rg3 and Rh2 belong to the 
20(S)-protopanaxadiol group, whereas eleven subtypes of ginsenosides including Re, Rf, Rg1, Rg2 and 
Rh1 belong to the 20(S)-protopanaxatriol group. Additionally, the oleanolic acid group contains 
ginsenoside Ro [2,9]. However, the concentration and bioactivities of ginsenosides in different 
ginsengs could vary by up to 20% [3]. The variability is related to the species, the part of the plant, 
the period of cultivation, and the processing method used [9,10]. Different pharmacological effects of 
ginsenosides have been reported and different combination of ginsenosides including 
20(S)-protopanaxadiol and 20(S)-protopanaxatriols have been used in treating inflammatory diseases [11]. 
Moreover, ginseng contains other compounds including phenolic compounds, polyacetylenes, 
ginsenoyne, sesquiterpenes, methoxypyrazine, alkylpyrazine derivatives, sesquiterpene alcohols, 
panasinsanols, β-caboline, and neutral or acidic polysaccharides [8,10]. 
3. Inflammation and Cytokines 
Inflammation is a complex biological response of our body to harmful external stimuli including 
microbial infections and chemical toxins. The inflammatory response is characterized by several steps 
including coordinate activation of signaling pathways, expression of proinflammatory cytokines, 
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chemokines and adhesion molecules in resident tissue cells, as well as infiltration of leukocytes 
mainly macrophages, neutrophils and dendritic cells and mediators of inflammation from the vascular 
system to remove the harmful stimuli and to initiate the healing process [12,13]. 
Leukocytes or endothelial cells produce proinflammatory or anti-inflammatory cytokines 
depending on their activities on regulating inflammation. Proinflammatory cytokines including tumor 
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) have been shown to play central roles in the 
pathogenesis of both acute and chronic inflammatory diseases [14,15]. Other proinflammatory 
cytokines include IL-17, IL-18 and the newly identified member of IL-1 family, IL-33, whereas 
anti-inflammatory cytokines including IL-10 and transforming growth factor-β negatively regulate or 
dampen the over-activated inflammatory responses [16-25]. 
TNF-α plays critical roles in the initiation and amplification of inflammatory response [26-29]. 
TNF-α signaling pathways are triggered by binding of TNF-α to one of the two distinct cell surface 
receptors, TNF-R1 and TNF-R2. TNF-R1 mediates largely the proinflammatory and apoptotic 
pathways activated by TNF-α, whereas TNF-R2 is associated with TNF-mediated tissue repair and 
angiogenesis. Following binding of TNF-α to TNF-R1, downstream signaling pathways are triggered 
by the recruitment of cytosolic adaptor proteins including receptor interacting protein, TNFR 
associated factor2, and FAS-associated death domain through specific protein-protein interaction 
domains. The protein signaling complexes recruit distinct enzymes resulting in the activation of 
different signaling pathways including caspases, the transcription factor nuclear factor-kappaB 
(NF-κB) and mitogen activated protein kinases (MAPK), and eventually induced transcription of 
inflammatory mediators [28]. 
4. Anti-Inflammatory Effects of Ginseng Extracts and Ginsenosides 
Ginseng extracts and the ginsenosides have been shown a wide range of beneficial effects against 
human diseases and their potential therapeutic effects have been attributed to its immunomodulatory, 
anti-oxidant and anti-inflammatory activities [30]. The anti-inflammatory effects of ginseng extracts 
and ginsenosides are associated with their properties of cytokine regulation and phagocytosis in innate 
immunity, as well as activation of T- and B- lymphocytes [31-36]. Moreover, reports have shown 
their adjuvant activities for different kinds of vaccines [9,37]. Previous reports of anti-inflammatory 
effects of ginseng extracts and ginsenosides will be described in following sections. 
4.1. Panax ginseng Extract 
Ginsan, the acid polysaccharide extract from ginseng, has been shown to have immunomodulatory 
effects in various reports. Ginsan inhibits the production of TNF-α, IL-1β, IL-6, IL-12, IL-18 and 
interferon-gamma (IFN-γ), and enhances the phagocytic activity of macrophages in Staphylococcus 
aureus-infected mice [38,39]. In addition, ginsan inhibits the activation of MAPK pathways including 
p38MAPK and c-Jun N-terminal kinases (JNK), and NF-κB in the infected mice [38]. Furthermore, 
ginsan is shown to have anti-asthmatic effects including reduction of airway hyperresponsiveness, and 
decreases of eosinophils in ovalbumin-treated mice. These effects are equivalent to those of 
dexamethasone treatment and could be partially mediated by enhancing the synthesis of 
cyclooxygenases and prostaglandin (PGE)2 [40]. 
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Ginsan exerts protective effects on mice with carbon tetrachloride-induced liver injury via 
inhibition of carbon tetrachloride-induced cytochrome P450 pathways and lipid peroxidation. In 
addition, ginsan attenuates the production of proinflammatory cytokines including IL-1β, IFN-γ and 
chemokines including monocyte chemoattractant protein (MCP)-1/CCL-2, macrophage inflammatory 
protein (MIP)-2β/CXCL-2 and KC/CXCL-1 leading to reduce leukocyte infiltration and inflammatory 
response [41]. However, ginsan stimulates the expression of IL-12, TNF-α and Major 
Histocompatibility Complex (MHC) class II molecules in murine dendritic cells and the proliferation 
of allogeneic CD4(+) T lymphocytes [42]. 
4.2. Panax Notoginseng Extracts 
The anti-atherosclerotic and anti-arthritic effects of Panax notoginseng saponins (PNS) in rodents 
have been reported recently. PNS show anti-atherosclerotic effects on apolipoprotein E-deficient mice. 
The levels of serum lipid, IL-6 and TNF-α in PNS-treated mice are lower than those of control mice. 
The anti-atherosclerotic effects of PNS could be due to the inhibition of TNF-α induced monocyte 
adhesion and the expression of endothelial adhesion molecules including vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) [7]. In addition, PNS is 
shown to attenuate the pathological changes of atherosclerosis induced by zymosan A in rat. The 
expression levels of integrins, IL-18, IL-1β, matrix metalloproteinase-2 (MMP-2), MMP-9, and 
NF-κB are decreased in PNS-treated rats [6]. On the other hand, PNS attenuates the degree of hepatic 
fibrosis in mice treated with carbon tetrachloride. The levels of serum transforming growth factor-β1, 
TNF-α and IL-6 decrease in PNS-treated mice compared with the control mice whereas the level of 
IL-10 increases, suggesting that PNS has certain therapeutic effects on hepatic fibrosis by regulating 
the imbalance of pro-fibrotic and anti-fibrotic cytokines [43]. BT-201, n-butanol extract of Panax 
notoginseng, has been shown the anti-arthritic effects on collagen-induced arthritis (CIA) mice [5]. 
BT-201 also decreases the production of TNF-α, IL-1β, inducible nitric oxide, and MMP-13, possibly 
via the suppression of NF-κB, ERK, p38 MAPK and JNK activation [5]. Moreover, the ethanol 
extract of Panax notoginseng roots inhibits the expressions of TNF-α, IL-6 and CD40 in DC2.4 
murine dendritic cells stimulated by Toll-like receptor ligands including lipopolysachharide (LPS), 
CpG and/or polyriboinosinic-polyribocytidylic acid [poly(I:C)]. However, the underlying mechanisms 
of the anti-inflammatory effects of Panax notoginseng extracts remains investigated [44]. 
4.3. Panax Quinquefolius Extracts 
The ethanol extract of Panax quinquefolius selectively inhibits the expression of iNOS in 
RAW264.7 cells induced by LPS by suppressing the Signal Transducers and Activators of 
Transcription protein (STAT)/iNOS signaling pathways [45]. Another report shows that the ethanol 
extracts of Panax quinquefolius can suppress the expression of inducible nitric oxide synthase (iNOS), 
cyclooxygenase-2 (COX-2) and p53 in mice with experimental colitis. The mucosal and DNA damage 
associated with colitis in these mice are also suppressed by the Panax quinquefolius extract [46]. 
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4.4. Rb1 
Ginsenoside Rb1 inhibits the over-expression of VCAM-1 and over-production of superoxide anion 
in TNF-α treated endothelial cells by suppressing MAPK and NF-κB signaling pathways [47]. Rb1 
also inhibits the productions of inflammatory mediators including IL-8 and PGE₂ in HaCaT human 
keratinocytes induced by capsaicin [48]. Rb1 inhibits capsaicin-induced calcium influx and NF-κB 
activity through capsaicin receptor also known as transient receptor potential channel vanilloid 
subtype 1 signaling pathways [48]. 
The anti-arthritic effect of Rb1 has been reported in collagen-induced arthritis CIA mice. Rb1 
inhibits TNF-α induction in peripheral blood mononuclear cells, fibroblast-like synoviocytes, and 
chondrocytes stimulated by IFN-γ, LPS or IL-1β. In addition, Rb1 suppresses the severity of 
inflammatory response in CIA mice by reducing TNF-α expression, cartilage destruction and cell 
infiltration in the arthritic joints of the mice [49]. 
4.5. Rd 
Ginsenoside Rd has been shown neuroprotective effects on a rat model of transient focal cerebral 
ischemia. Rd reduces the accumulation of the early detected oxidative DNA, protein and lipid 
peroxidation products in rats subjected to transient middle cerebral artery occlusion. Rd suppresses the 
inflammatory responses by inhibiting expressions of iNOS and COX-2 and microglial activation [50]. 
4.6. Rg1 
Ginsenoside Rg1 inhibits the expression of TNF-α, iNOS and ionized calcium binding adaptor 
molecule-1 in both cerebral cortex and hippocampus in mice intracerebroventricular injected of LPS 
by suppressing NF-κB and MAPK pathways [51]. Consistent report shows that Rg1 suppresses 
NF-κB pathways leading to decrease production of TNF-α and nitric oxide in N9 microglial cells 
induced by LPS. Rg1 can be a potent inhibitor of microglial cells activation-mediated  
neuro-degenerative diseases [52]. On the other hand, Rg1 induces Th1 dominant cytokines production 
such as IFN-γ and IL-2 in CD4(+) T cells of mice infected with Candida albicans. Such activities 
help the host to resist the risk of dissemination of candidiasis [53]. 
4.7. Rg3 
Ginsenoside Rg3 inhibits the COX-2 expression as well as NF-κB and activator protein-1 
activations in 12-O-tetradecanoylphorbol-13-acetate-induced mouse skin and human promyelocytic 
leukemia cells [54]. Rg3 also reduces TNF-α, IL-1β, IL-6, MCP-1, MIP-1γ expressions in BV-2 
murine microglial cells treated with beta-amyloid, indicating that Rg3 prevents neurotoxicity by 
inhibiting proinflammatory cytokines production in microglial cells [55]. Rg3 may have 
anti-atherosclerotic activities in the vasculature. Rg3 suppresses the expressions of TNF-α induced 
VCAM-1 and ICAM-1 in ECV 304 human endothelial cells and prevents the endothelial cells 
undergo apoptosis through the Akt-mediated, caspases-activated pathways [56,57]. 
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4.8. Rh1 
Ginsenoside Rh1 may provide beneficial effects on neuroinflammatory diseases by modulating the 
microglial activation. Rh1 suppresses production of nitric oxide, reactive oxygen species and TNF-α 
in BV2 microglial cells induced by IFN-γ. The study for iNOS promoter shows that IFN-γ-activated 
JAK/STAT and ERK signaling pathways, and their downstream transcription factors including 
NF-κB, interferon regulatory factor-1 and STAT1 was inhibited by Rh1 [58]. In addition, Rh1 induces 
expressions of IL-10 and hemeoxygenase-1 expression via activation of cAMP-dependent protein 
kinase signaling pathways. On the other hand, Rh1 inhibits activation of NF-κB and extracellular 
signal regulated kinase (ERK1/2) signaling pathways and expressions of iNOS and COX-2 in 
LPS-stimulated microglia [59]. Hence, the anti-inflammatory effects of Rh1 alleviate the severity of 
neuro-degenerative diseases. 
A recent report shows that Rh1 can alleviate inflammatory symptoms in oxazolone-induced atopic 
dermatitis-like skin lesions in hairless mice by suppressing the level of IgE and IL-6 in peripheral 
blood [60]. Additionally, Rh1 reduces histamine release in rat peritoneal mast cells and the 
IgE-mediated passive cutaneous anaphylaxis reaction in mice [61]. The anti-allergic effects of Rh1 
may due to anti-inflammatory activities since Rh1 inhibits the expression of iNOS and COX-2 in 
LPS-induced RAW264.7 murine macrophages by preventing phosphorylation and degradation of the 
inhibitor of NF-κB (I-κB) [61,62]. 
4.9. Rh2 and Rh3 
Ginsenoside Rh2 has specific inhibitory effects on activation of NF-κB and JNK signaling 
pathways in human astroglial cells-induced by TNF-α [63]. In addition, Rh2 inhibits the DNA binding 
activity of activator protein 1 (AP-1) and production of nitric oxide, COX-2, TNF-α and IL-1β in BV2 
cells induced by LPS and IFN-γ. On the other hand, Rh2 can increase the expression of IL-10 in BV2 
cells [64]. Ginsenosides Rh2 and Rh3 significantly inhibit LPS-induced microglial cells activation by 
suppressing expression of inflammatory mediators including iNOS, MMP-9, TNF-α, and IL-1β [65]. 
4.10. Rp1 
Ginsenoside Rp1 is a newly reported ginsenoside derivative that show inhibitory effects on IL-1β 
expression in LPS-treated RAW264.7 cells by blocking the activation of NF-κB signaling pathways [66]. 
Our recent report demonstrated that the ethanol extract of Panax ginseng inhibits expressions of 
TNF-α-inducible cytokines and signaling proteins in human promonocytic cells. Ginseng extract 
suppresses TNF-α-induced chemokine CXCL-10 expression by inactivating the ERK1/2 pathway. 
We also showed that the suppressive effect of ginseng extract on TNF-α induced-CXCL-10 
transcription could be due to the collective effects of ginsenosides mixtures instead of a single 
ginsenoside [67]. The inflammatory study models, targeted regulatory proteins and effects on 
inflammatory mediators for ginseng extracts and ginsenosides are summarized in Table 1. 
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Table 1. Summary of anti-inflammatory effects of ginseng extracts and ginsenosides. 
Ginseng 
extract/Ginsenoside 
Experimental model 
Regulatory 
proteins 
Effects on 
inflammatory 
mediators 
References 
Panax ginseng acid  
polysaccharide extract 
Ovalbumin-treated mice - 
↓Cyclooxygenases, 
PGE2 
[40] 
Panax ginseng acid  
polysaccharide extract 
Staphylococcus 
aureus-infected mice 
p38MAPK, JNK 
and NF-κB 
↓IL-1β, IL-6, IL-12, 
IL-18, IFN-γ  [38,39] 
Panax ginseng acid  
polysaccharide extract 
Carbon 
tetrachloride-induced mice 
- 
↓CCL-2, CXCL-2, 
CXCL-1 
[41] 
Panax ginseng acid  
polysaccharide extract 
Murine dendritic cells - 
↑IL-12, TNF-α, 
MHC-II 
[42] 
Panax ginseng  
ethanol extract 
TNFα-induced U937 cells ERK ↓CXCL-10 [67] 
Panax notoginseng  
Saponins 
Apolipoprotein-E deficient 
mice 
- 
↓IL-6, TNF-α, 
VCAM, ICAM 
[7] 
Panax notoginseng  
Saponins 
Zymosan A-induced mice NF-κB 
↓MMP-2, MMP-9, 
IL-18, IL-1β, 
integrins 
[6] 
Panax notoginseng  
Saponins 
Carbon 
tetrachloride-induced mice 
- 
↓TGF-β, TNF-α, 
IL-6 
↑IL-10 
[43] 
Panax notoginseng  
n-butanol extract 
Collagen-induced arthritis 
mice 
p38MAPK, 
JNK, ERK and 
NF-κB 
↓TNF-α, IL-1β, 
iNOS, MMP-13 
[5] 
Panax notoginseng  
ethanol extract 
LPS, CpG or 
poly(I:C)-induced  
DC2.4 murine dendritic 
cells 
- 
↓IL-6, TNF-α, 
CD40 
[44] 
Panax quinquefolius 
ethanol extract 
LPS-induced RAW murine 
macrophages 
STAT ↓iNOS [45] 
Panax quinquefolius 
ethanol extract 
Experimental colitis mice - ↓iNOS, COX-2, p53 [46] 
Rb1 
TNF-induced endothelial 
cells 
MAPK and 
NF-κB ↓TNF-α [47] 
Rb1 
Capsaicin-induced HaCaT 
human keratinocyte 
NF-κB ↓IL-8, PGE2 [48] 
Rb1 
IFN-γ, LPS/IL-1β−induced 
CIA mice 
- 
↓TNF-α  in PBMC, 
fibroblast-like 
synoviocytes and 
chondrocytes 
[49] 
Rd 
Transient focal cerebral 
ischemia 
- ↓iNOS, COX-2 [50] 
Rg1 LPS-injected mice 
p38MAPK, JNK 
and NF-κB 
↓TNF-α, iNOS and 
ionized calcium 
binding adaptor 
molecule-1 
[51] 
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Table 1. Cont. 
Rg1 LPS-N9 microglial cells NF-κB ↓TNF-α, nitric oxide [52] 
Rg1 
CD4(+) T cells of Candida 
albicans-infected mice 
- ↑IL-2, IFN-γ  [53] 
Rg3 
TPA-induced mouse skin 
cells and U937 
promyelocytic leukemia 
cells 
AP-1, NF-κB ↓COX-2 [54] 
Rg3 
Beta-amyloid-induced BV2 
murine microglial cells  
- 
↓TNF-α, IL-1β, 
IL-6, MCP-1, MIP-1γ  [55] 
Rg3 
TNF-α-induced-ECV304 
human endothelial cells 
AKT 
↓VCAM-1, 
ICAM-1 
[56,57] 
Rh1 
IFN-γ-BV2 murine 
microglial cells  
ERK, STAT1, 
IRF-1 and 
NF-κB 
↓Nitric oxide, 
reactive oxygen 
species, TNF-α 
[58] 
Rh1 LPS-stimulated microglia 
cAMP-depende
nt protein kinase 
↑IL-10, 
hemeoxygenase-1 
[59] 
Rh1 LPS-stimulated microglia ERK and NF-κB ↓iNOS, COX-2 [59] 
Rh1 
Oxazolone-induced atopic 
dermatitis skin lesion in 
mice 
- 
↓IL-6, IgE in 
peripheral blood 
↑Foxp3  
[60] 
Rh1 
LPS-induced RAW murine 
macrophages 
NF-κB ↓iNOS, COX-2 [61,62] 
Rh2 
TNF-α-induced human 
astroglial cells 
JNK and NF-κB - [63] 
Rh2 
LPS/IFN-γ-induced BV2 
microglial cells  
AP-1 
↓Nitric oxide, 
COX-2, TNF-α, 
IL-1β 
[64] 
Rh2 
Rh2-induced BV2 murine 
microglial cells  
- ↓IL-10 [64] 
Rh2 & Rh3 
LPS-induced microglial 
cells 
- 
↓iNOS, MMP-9, 
IL-1β,TNF-α [65] 
Rp1 
LPS-induced RAW murine 
macrophages 
NF-κB ↓IL-1β [66] 
AP-1: activator protein 1; COX: cyclooxygenase; ERK: extracellular signal regulated kinase;  
ICAM: intercellular cell adhesion molecule; iNOS: inducible nitric oxide synthase; JNK: c-Jun N-terminal 
kinases; LPS: lipopolysaccharide; MAPK: mitogen activated protein kinases; MCP: monocyte 
chemoattractant protein; MHC: major histocompatibility complex; MIP: macrophage inflammatory protein; 
MMP: matrix metalloproteinase; NF-kB: nuclear factor-kappaB; PGE: prostaglandin; PBMC: peripheral blood 
mononuclear cells; STAT: Signal Transducers and Activators of Transcription protein; TGF: Transforming 
growth factor; TNF: tumor necrosis factor; TPA: 12-O-tetradecanoylphorbol-13-acetate; VCAM: vascular 
cell adhesion molecule; ↓: downregulation of expression; ↑: upregulation of expression. 
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5. Application of Ginseng and Ginsenoside to TNF-α Mediated Inflammatory Diseases 
TNF-α is a pleiotropic cytokine and its biological functions are varied and complex. It interacts 
with an array of other cytokines to initiate a cascade of cellular activities downstream. TNF-α induces 
expressions of vascular adhesion molecules on the endothelial cells and chemokines on macrophages 
and neutrophils to enhance cell trafficking [68-72]. In addition, TNF-α stimulates phagocytic 
functions of monocytes and macrophages to clear invading pathogens or cell debris. Hence, TNF-α 
production in acute infection is mostly beneficial to the host. However, excess uncontrolled 
production of TNF-α can cause over-induction of cytokines and chemokines including IL-1, IL-6, 
IL-8, growth-regulated oncogene, CXCL-10 and CCL-5. Additionally, the release of glucocorticoids 
may enhance local inflammation and cause tissue damage [14,73]. Several autoimmune and 
inflammatory diseases including rheumatoid arthritis [72], septic shock [74], Crohn’s disease, 
psoriasis [75], and inflammatory bowel disease [76,77] are associated with dysregulated TNF-α 
production. As TNF-α is a good therapeutic target for treating inflammatory diseases, the 
identification of TNF-α antagonists from medicinal herbs and natural products, for example ginseng, 
could definitely provide an alternative for the treatment of debilitating inflammatory diseases. However, 
it has to emphasize that the anti-inflammatory effects of ginseng and/or ginsenosides cannot be 
attributed to lowering TNF-α only but also their immunoregulatory properties on innate and adaptive 
immunity as mentioned earlier. 
6. Conclusions 
Ginseng contains a complex mixture of chemical constituents that have multiple and diverse 
physiological effects on the human body. The anti-atherosclerotic, anti-arthritic, anti-oxidative and 
anti-allergic effects of ginseng and the ginsenosides in in vitro and in vivo studies may due to the their 
anti-inflammatory activity. However, the detailed molecular mechanisms of the anti-inflammatory 
activities of ginseng extracts and ginsenosides remain to be investigated. 
During the last few decades, bioactivity-guided approach have been widely applied for isolation or 
identification of the bioactive compounds from herbs [78]. This approach can be extended further to 
another level by combining the different bioassay and the rapidly developed liquid chromatography 
and tandem mass spectrometry, and liquid chromatography and nuclear magnetic resonance 
technologies to determine not only the native bioactive compounds in medicinal herbs but also their 
structural interactions to the targets at the molecular level [79]. 
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